Future directions in the clinical management of amyloid light-chain amyloidosis

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989. Blood 1992;79:1817–1822.
   PubMed Web of Science ®Google Scholar
• Comenzo RL. How I treat amyloidosis. Blood 2009;114: 3147–3157.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010:287–294.
   Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121: 5124–5130.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Allaying and alleviating amyloid agony and anxiety. Blood 2013;121:3301–3302.
   PubMed Web of Science ®Google Scholar
• Geertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013; 88:416–425.
   PubMed Web of Science ®Google Scholar
• Perfettini V, Caserne S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII]) as a new amyloid-associated germline gene segment. Blood 2002;100: 948–953.
   PubMed Web of Science ®Google Scholar
• Madin S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clinic Proc 2012;83:232–238.
   Google Scholar
• Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Prog 2004: 257–282.
   Google Scholar
• Perfetti V, Ubbiali P, Vignarelli MC, et al. Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 1998;91:2948–2954.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82: 1501–1505.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420–3427.
   PubMed Web of Science ®Google Scholar
• Leung N, Glavey SV, Kumar S, et al. A detailed evaluation of the current renal response criteria in AL amyloidosis:is it time for a revision?Haematologica 2013;98:988–992.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006;1:1331–1341.
   PubMed Web of Science ®Google Scholar
• Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?Diagn Cytopathol 2004;30:178–181.
   PubMed Web of Science ®Google Scholar
• Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274–278.
   Google Scholar
• United Kingdom Myeloma Forum on behalf of the British Committee for Standards in Haematology (BCSH). Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125:681–700.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Gallimore R, Gilmore RD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78–84.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79: 319–328.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of free light chains are prognostic in patients with primary amyloidosis undergoing peripheral blood stem cell transplant. Blood 2006;107: 3378–3383.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry- based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957–4959.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30: 989–995.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.
   PubMed Web of Science ®Google Scholar
• Merlini G, Wachalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood121;26: 5124–5130.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–4549.
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–2445.
   PubMed Web of Science ®Google Scholar
• Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010;116:3426–3430.
   PubMed Web of Science ®Google Scholar
• Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematatol 2012;87:465–471.
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Steingart RM, Comenzo RL, et al. Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. Am J Cardiol 2012;110:1180–1184.
   PubMed Web of Science ®Google Scholar
• Pantel K, Riethdorf S. Pathology: are circulating tumor cells predictive of overall survival?Nat Rev Clin Oncol 2009;6:190–191.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213–3221.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 2004;351:781–791.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Dhodapkar MV, Kyle RA, et al. Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993;72: 108–113.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Witzig TE, Schroeder G, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003;101:827–830.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780–1787.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. Long term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 1999;93: 1062–1066.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned. Leuk Lymphoma 2000;37:245–258.
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, et al. High- dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;40:85–93.
   Google Scholar
• Cohen AD, Comenza RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis and therapy. Hematology Am Soc Hematol Educ Program 2010:287–294.
   Google Scholar
• Cohen AD, Zhou P, Chou J, et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007;139:224–233.
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood 2005;105:2949–2951.
   Google Scholar
• Gibbs SDJ, Gillmore JD, Sattianayagam PT, et al. In AL amyloidosis, both oral melphalan and dexamethasone (Mel-Dex) and risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) have similar efficacy as upfront treatment Blood 2009; 114(Suppl. 1): Abstract 745.
   Google Scholar
• Schechter G. A triple on AL amyloidosis, waiting for a home run. Blood 2007;109:391–392.
   Web of Science ®Google Scholar
• Sanchorawala V, Finn KT, Fennessey S, et al. Durable haematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Amyloid 2010;17(Suppl. 1): Abstract 84.
   Google Scholar
• Hegenbart U, Bochtler T, Dietrich S, et al. Treatment of light chain amyloidosis patients with lenalidomide and dexamethasone after failure of melphalan-containing chemotherapies. Amyloid 2010;17(Suppl. 1): Abstract 184.
   Google Scholar
• Russo P, Palladini G, Zenone Bragotti L, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis. Amyloid 2010; 17(Suppl. 1): Abstract 154.
   Google Scholar
• Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118:4346–4352.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 2010;51:2181–2187.
   PubMed Web of Science ®Google Scholar
• Roy V. Autologous stem cell transplant for AL amyloidosis. Bone Marrow Res 2012;2012:238961.
   PubMedGoogle Scholar
• Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011;118:865–873.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083–1093.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008;358:91–93.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109: 457–464.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025–1031.
   PubMed Web of Science ®Google Scholar
• Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5:596–613.
   PubMed Web of Science ®Google Scholar
• Ciechanover A. From the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79–86.
   PubMed Web of Science ®Google Scholar
• Eytan E, Ganoth D, Armon T, et al. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci USA 1989;86: 7751–7755.
   PubMed Web of Science ®Google Scholar
• Driscoll J, Goldberg AL. The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J Biol Chem 1990; 265:4789–4792.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2006;61:3071–3076.
   Google Scholar
• Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 1649–1657.
   Google Scholar
• Dick LR, Fleming PE. Building on bortezomib:second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010;15:243–249.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
   PubMed Web of Science ®Google Scholar
• Yaqub S, Ballester G, Ballester O. Frontline Therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials. Cancer Invest 2013;31:529–537.
   PubMed Web of Science ®Google Scholar
• De la Puente P, Azab AK. Contemporary drug therapies for multiple myeloma. Drugs Today 2013;499:563–573.
   Google Scholar
• Wechalekar AD, Lachmann HJ, Offer M, et al.Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93:295–298.
   PubMed Web of Science ®Google Scholar
• Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114:1489–1497.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Finishing off fibrils. Blood 2009;114:1456–1457.
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119:4387–4390.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone [CyBorD] produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391–4394.
   PubMed Web of Science ®Google Scholar
• Merlini, G. CyBorD: stellar response rates in AL amyloidosis. Blood 2012;119:4343–4345.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide. Ann Hematol 2012;91:89–92.
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Goodman H, Lachmann H, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457–464.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009;88:347–350.
   PubMed Web of Science ®Google Scholar
• Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010;116:4777–4782.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012; 119:4860–4867.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012;119:5384–5390.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013;98: 433–436.
   PubMed Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70:1970–1980.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Berdeja JG, Niesvizky R, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma. Blood 2012;120(Suppl. 1): Abstract 332.
   Google Scholar
• Merlini G, Sanchorawala V, Zonder JA. MLN9708, a novel, investigational oral proteasome inhibitor, in patients with relapsed or refractory light-chain amyloidosis: results of a phase 1 study. Blood 2012;120(Suppl. 1): Abstract 731.
   Google Scholar
• Study of oral MLN9708 in adult patients with relapsed or refractory light chain amyloidosis. Available from: http://clinicaltrials.gov/show/NCT01318902
   Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281–3290.
   PubMed Web of Science ®Google Scholar
• Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc Natl Acad Sci USA 1999;96:10403–10408.
   PubMed Web of Science ®Google Scholar
• PX-171-003-A1, an open-label, single-arm, phase II study of carfilzomib in patients with relapsed and refractory multiple myeloma:Long-term follow-up and subgroup analysis. J Clin Oncol 2011;29(15 Suppl.): Abstract 8027.
   Google Scholar
• Gertz MA, Buadi FK, Hayman SR.Treatment of immunoglobulin light chain (primary or AL) amyloidosis. Oncology (Williston Park) 2011;25:620–626.
   PubMed Web of Science ®Google Scholar
• A safety study of carfilzomib in patients with previously-treated systemic light chain amyloidosis. Available from: http://clinicaltrials.gov/ct2/show/NCT01789242
   Google Scholar
• Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93–97.
   PubMed Web of Science ®Google Scholar
• Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347–361.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74–82.
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854–3858.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis:colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336: 1202–1207.
   PubMed Web of Science ®Google Scholar
• Dubrey S, Burke M, Hawkins P, et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23:1142–1153.
   PubMed Web of Science ®Google Scholar
• Kpodonu J, Massad MG, Caines A, et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763–1765.
   PubMed Web of Science ®Google Scholar
• Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish Registry for Heart Transplantation. Am J Transplant 2009;9:1414–1419.
   Google Scholar
• Lacy MQ, Leung N. Supportive care of amyloidosis. In: Gertz M, Rajkumar SV, editors. Amyloidosis: diagnosis and treatment (contemporary hematology). New York: Springer; 2010. pp. 65–76.
   Google Scholar
• Herlihy JP, Loyalka P, Gnananandh J, et al. PleurX catheter for the management of refractory pleural effusions in congestive heart failure. Tex Heart Inst J 2009;36:38–43.
   PubMed Web of Science ®Google Scholar
• Perz JB, Kristen AV, Rahemtulla A, et al. Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol 2006;95:671–674.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103:3960–3963.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Schönland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116: 522–528.
   Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis:colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202–1207.
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936–2938.
   PubMed Web of Science ®Google Scholar